However, recently additional mechanisms have been proposed to explain the immunotherapeutic effect of anti-CTLA-4 mAbs including Fc receptor-dependent depletion of regulatory T (Treg) cells in tumor microenvironment, and blocking of trans-endocytosis of B7 on dendritic cells (DC) (62–66). The gene discussed is CD80; the disease is neoplasm.